Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blasco-Turrión Sara, Crespo-Leiro Maria Generosa, Donoso Trenado Víctor, Chi Hion Pedro Li, Díaz Molina Beatriz, Roura Gerard, Álvarez-Osorio Manuel Pan, Gómez-Bueno Manuel, Ortiz Bautista Carlos, Diaz Jose F, Garrido Bravo Iris Paula, Moreno Raúl, Sarnago-Cebada Fernando, Salterain González Nahikari, de la Torre Hernandez Jose M, García Del Blanco Bruno, Farrero Marta, Ortas Nadal Rosario, Martin Pedro, de La Fuente Luis, Sanz-Sánchez Jorge, Mirabet Pérez Sònia, Alonso Fernández Vanesa, Gómez Hospital Joan Antoni, López Granados Amador, Couto-Mallon David, Del Trigo Espinosa María, Rangel Sousa Diego, Zatarain-Nicolás Eduardo, Arzamendi Aizpurua Dabit, López Vilella Raquel, San Román J Alberto, Amat-Santos Ignacio J
Аннотация
AIMS: To provide insights on structural transcatheter procedures performed across HTx and LVAD patients in Spain.
METHODS: Multicenter, ambispective, observational nationwide registry.
RESULTS: Until May/2023, 36 percutaneous structural interventions were performed (78% for HTx and 22% for LVAD) widely varying among centers (0%-1.4% and 0%-25%, respectively). Percutaneous mitral transcatheter edge-to-edge (TEER) was the most common (n = 12, 33.3%), followed by trancatheter aortic valve replacement (n = 11, 30.5%), and tricuspid procedures (n = 9, 25%). Mitral TEER resulted in mild residual mitral regurgitation in all but one case, mean gradient was <5 mmHg in 75% of them at 1-year, with no mortality and 8.3% re-admission rate. Tricuspid TEER resulted in 100% none/mild residual regurgitation with a 1-year mortality and readmission rates of 22% and 28.5%, respectively. Finally, trancatheter aortic valve replacement procedures (n = 8 in LVADs due to aortic regurgitation and n = 3 in HTx), were successful in all cases with one prosthesis degeneration leading to severe aortic regurgitation at 1-year, 18.2% mortality rate and no re-admissions. Globally, major bleeding rates were 7.9% and 12.5%, thromboembolic events 3.7% and 12.5%, readmissions 37% and 25%, and mortality 22% and 25%, in HTx and LVADs respectively. No death was related to the implanted transcatheter device.
CONCLUSIONS: Most centers with HTx/LVAD programs perform structural percutaneous procedures but with very inconsistent incidence. They were associated with good safety and efficacy, but larger studies are required to provide formal recommendations.